BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hwang JP, Barbo AG, Perrillo RP. Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases. J Viral Hepat. 2015;22:346-352. [PMID: 25220947 DOI: 10.1111/jvh.12305] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Perrillo RP. Hepatitis B reactivation from immunosuppressive drug therapy: A global menace: Editor’s comment for february issue of clinical liver disease. Clinical Liver Disease. 2015;5:39-42. [PMID: 31040946 DOI: 10.1002/cld.448] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
2 Khaderi SA, Hollinger FB. Is the Risk of Death Enhanced in Immunosuppressed Hepatitis B Virus-infected Patients Who Develop Acute Liver Failure? Clin Gastroenterol Hepatol 2017;15:123-6. [PMID: 27693523 DOI: 10.1016/j.cgh.2016.09.141] [Reference Citation Analysis]
3 Gonzalez SA, Perrillo RP. Hepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy. Clin Infect Dis. 2016;62 Suppl 4:S306-S313. [PMID: 27190320 DOI: 10.1093/cid/ciw043] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
4 Sarmati L, Andreoni M, Antonelli G, Arcese W, Bruno R, Coppola N, Gaeta GB, Galli M, Girmenia C, Mikulska M, Pane F, Perno CF, Picardi M, Puoti M, Rambaldi A, Svicher V, Taliani G, Gentile G. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. Clin Microbiol Infect. 2017;23:935-940. [PMID: 28668466 DOI: 10.1016/j.cmi.2017.06.023] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 9.8] [Reference Citation Analysis]
5 Chaulet P. Tuberculosis: a six-month cure. World Health Forum. 1989;10:116-122. [PMID: 2665766 DOI: 10.1016/j.critrevonc.2015.10.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis]
6 Yuan BH, Li RH, Yuan WP, Xiang BD, Zheng MH, Yang T, Zhong JH, Li LQ. Perioperative entecavir for patients with HBV-related hepatocellular carcinoma and low levels of viral DNA: analysis using propensity score matching. Oncotarget 2017;8:51810-6. [PMID: 28881690 DOI: 10.18632/oncotarget.15395] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
7 Haider M, Flocco G, Lopez R, Carey W. Retrospective observational study of temporal trends and outcomes of hepatitis B screening in patients receiving rituximab. BMJ Open 2020;10:e043672. [PMID: 33323450 DOI: 10.1136/bmjopen-2020-043672] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Caniza MA, Odio C, Mukkada S, Gonzalez M, Ceppi F, Chaisavaneeyakorn S, Apiwattanakul N, Howard SC, Conter V, Bonilla M. Infectious complications in children with acute lymphoblastic leukemia treated in low-middle-income countries. Expert Rev Hematol 2015;8:627-45. [PMID: 26211675 DOI: 10.1586/17474086.2015.1071186] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
9 Cobb BR, Valsamakis A. Chronic Hepatitis B, C, and D. Microbiol Spectr 2016;4. [PMID: 27726758 DOI: 10.1128/microbiolspec.DMIH2-0025-2015] [Reference Citation Analysis]
10 Rolston KV. Infections in Cancer Patients with Solid Tumors: A Review. Infect Dis Ther. 2017;6:69-83. [PMID: 28160269 DOI: 10.1007/s40121-017-0146-1] [Cited by in Crossref: 89] [Cited by in F6Publishing: 77] [Article Influence: 17.8] [Reference Citation Analysis]
11 Hilal T, Gea-banacloche JC, Leis JF. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections. Blood Reviews 2018;32:387-99. [DOI: 10.1016/j.blre.2018.03.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
12 Borojevic B, Chauhan A, Patterson S. Liver failure from delayed hepatitis B reactivation in anti-HBc-positive patient following rituximab for B-cell lymphoma. BMJ Case Rep 2021;14:e243526. [PMID: 34244190 DOI: 10.1136/bcr-2021-243526] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Randhawa JK, Ferrajoli A. A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia. Expert Rev Hematol 2016;9:235-44. [PMID: 26652692 DOI: 10.1586/17474086.2016.1129893] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Yu S, Luo H, Pan M, Luis AP, Xiong Z, Shuai P, Zhang Z. Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis. Int J Clin Pharm 2016;38:1035-43. [PMID: 27450506 DOI: 10.1007/s11096-016-0358-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
15 Mahmoud HK, Fathy GM, Elhaddad A, Fahmy OA, Abdel-Mooti M, Abdelfattah R, Bokhary M. Hematopoietic Stem Cell Transplantation in Egypt: Challenges and Opportunities. Mediterr J Hematol Infect Dis 2020;12:e2020023. [PMID: 32395212 DOI: 10.4084/MJHID.2020.023] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Gentile G, Andreoni M, Antonelli G, Sarmati L. Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: a systematic review. Clin Microbiol Infect 2017;23:916-23. [PMID: 28668465 DOI: 10.1016/j.cmi.2017.06.024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
17 Jasmine Bullard A, Cunningham FE, Volpp BD, Lowy E, Beste LA, Heron BB, Geraci M, Hammond JM, LaPlant K, Stave EA, Turner MJ, O'Leary MC, Kelley MJ, Hunt CM. Preventing Hepatitis B Reactivation During Anti-CD20 Antibody Treatment in the Veterans Health Administration. Hepatol Commun 2018;2:1136-46. [PMID: 30202826 DOI: 10.1002/hep4.1238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Wani MA, Sodhi JS, Yatoo GN, Shah A, Geelani S, Zargar SA, Gulzar GM, Khan M, Aziz SA. Clinical Profile and Efficacy of Antivirals in Hepatitis B Virus Reactivation, in Patients With Cancer Receiving Chemotherapy. J Clin Exp Hepatol 2020;10:590-8. [PMID: 33311896 DOI: 10.1016/j.jceh.2020.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Gentile G, Antonelli G. HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review. Viruses. 2019;11. [PMID: 31717647 DOI: 10.3390/v11111049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
20 De Conto F, Buttrini M, Dell'Anna ML, Maccari C, Montanari G, Arcangeletti MC, Martinelli M, Chezzi C, Calderaro A. DETECTION OF OCCULT HEPATITIS B VIRUS INFECTION AMONG SUBJECTS WITH ISOLATED HEPATITIS B CORE ANTIBODIES: RESULTS FROM A 3-YEAR SURVEY IN AN ITALIAN TERTIARY-CARE HOSPITAL. Clin Res Hepatol Gastroenterol 2022;:101892. [PMID: 35202845 DOI: 10.1016/j.clinre.2022.101892] [Reference Citation Analysis]
21 Debarry J, Cornberg M, Manns MP. Challenges in warranting access to prophylaxis and therapy for hepatitis B virus infection. Liver Int 2017;37 Suppl 1:67-72. [PMID: 28052625 DOI: 10.1111/liv.13320] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
22 Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2019;133:137-146. [PMID: 30341058 DOI: 10.1182/blood-2018-04-848044] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 11.8] [Reference Citation Analysis]
23 Lin CL, Kao JH. Hepatitis B reactivation in patients receiving immunosuppressive therapy: a hidden menace. Hepatol Int 2017;11:31-3. [PMID: 28058576 DOI: 10.1007/s12072-016-9782-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
24 Arora A, Anand AC, Kumar A, Singh SP, Aggarwal R, Dhiman RK, Aggarwal S, Alam S, Bhaumik P, Dixit VK, Goel A, Goswami B, Kumar A, Kumar M, Madan K, Murugan N, Nagral A, Puri AS, Rao PN, Saraf N, Saraswat VA, Sehgal S, Sharma P, Shenoy KT, Wadhawan M; Members of the INASL taskforce on Hepatitis B. INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids. J Clin Exp Hepatol 2018;8:403-31. [PMID: 30568345 DOI: 10.1016/j.jceh.2018.06.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
25 Feuchtenberger M, Schäfer A, Philipp Nigg A, Rupert Kraus M. Hepatitis B Serology in Patients with Rheumatic Diseases. Open Rheumatol J 2016;10:39-48. [PMID: 27708728 DOI: 10.2174/1874312901610010039] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
26 Perrillo R. Invited Commentary: Screening for hepatitis B in the immigrant population and individuals who are in need of immunosuppressive drug therapy. Proc (Bayl Univ Med Cent) 2015;28:443-4. [PMID: 26424936 DOI: 10.1080/08998280.2015.11929302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
27 Wang Q, Klenerman P, Semmo N. Significance of anti-HBc alone serological status in clinical practice. The Lancet Gastroenterology & Hepatology 2017;2:123-34. [DOI: 10.1016/s2468-1253(16)30076-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 4.2] [Reference Citation Analysis]
28 Cao X, Wang Y, Li P, Huang W, Lu X, Lu H. HBV Reactivation During the Treatment of Non-Hodgkin Lymphoma and Management Strategies. Front Oncol 2021;11:685706. [PMID: 34277431 DOI: 10.3389/fonc.2021.685706] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Chang KM, Liu M. Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics. Curr Opin Pharmacol 2016;30:93-105. [PMID: 27570126 DOI: 10.1016/j.coph.2016.07.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
30 Torres-Cornejo A, Lauer GM. Hurdles to the Development of Effective HBV Immunotherapies and HCV Vaccines. Pathog Immun 2017;2:102-25. [PMID: 28664194 DOI: 10.20411/pai.v2i1.201] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
31 Calvo PL, Pinon M, Dell'Olio D, Carpino A, Biasin E, Pizzol A, Catalano S, Peruzzi L, Rigazio C, Cisarò F, Opramolla A, Asaftei SD, Quarello P, Fagioli F. Management of Hepatitis-B Virus Infection in Immunocompromised Children: A Single Center Experience. J Pediatr Gastroenterol Nutr 2021;72:597-602. [PMID: 33399328 DOI: 10.1097/MPG.0000000000003042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Federico A, Brancaccio G, Dallio M, Iodice P, Fabozzi A, Del Prete S, Ciardiello F, Loguercio C, Gaeta GB. Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required? Dig Liver Dis 2017;49:197-201. [PMID: 27899262 DOI: 10.1016/j.dld.2016.11.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
33 Bessone F, Dirchwolf M. Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations. World J Hepatol 2016; 8(8): 385-394 [PMID: 27004086 DOI: 10.4254/wjh.v8.i8.385] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 7.7] [Reference Citation Analysis]
34 Junus K, Aguilar M, Patel P, Irwin D, Yee S, Liu B, Bhuket T, Wong RJ. Improvements in hepatitis B virus screening before rituximab therapy: A community-based, safety-net hospital experience. Cancer 2017;123:650-6. [PMID: 27696389 DOI: 10.1002/cncr.30381] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
35 Leonard AN, Love BL, Norris LB, Siddiqui SK, Wallam MN, Bennett CL. Screening for viral hepatitis prior to rituximab chemotherapy. Ann Hematol 2016;95:27-33. [PMID: 26382277 DOI: 10.1007/s00277-015-2502-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
36 An J, Shim JH, Kim SO, Choi J, Kim SW, Lee D, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis. J Med Virol. 2016;88:1576-1586. [PMID: 26945543 DOI: 10.1002/jmv.24512] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
37 Ghany MG, Feld JJ, Chang KM, Chan HLY, Lok ASF, Visvanathan K, Janssen HLA. Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. Lancet Gastroenterol Hepatol 2020;5:406-17. [PMID: 32057301 DOI: 10.1016/S2468-1253(19)30344-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 5.5] [Reference Citation Analysis]